- Home
- TSHA vs LAES Comparison
TSHA vs LAES Comparison
Compare TSHA & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- LAES
- Stock Information
- Founded
- TSHA 2019
- LAES 2022
- Country
- TSHA United States
- LAES Switzerland
- Employees
- TSHA N/A
- LAES N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- LAES Semiconductors
- Sector
- TSHA Health Care
- LAES Technology
- Exchange
- TSHA Nasdaq
- LAES Nasdaq
- Market Cap
- TSHA 334.1M
- LAES 307.1M
- IPO Year
- TSHA 2020
- LAES N/A
- Fundamental
- Price
- TSHA $1.72
- LAES $2.74
- Analyst Decision
- TSHA Strong Buy
- LAES Strong Buy
- Analyst Count
- TSHA 8
- LAES 1
- Target Price
- TSHA $6.63
- LAES $6.00
- AVG Volume (30 Days)
- TSHA 1.5M
- LAES 13.2M
- Earning Date
- TSHA 02-26-2025
- LAES 03-24-2025
- Dividend Yield
- TSHA N/A
- LAES N/A
- EPS Growth
- TSHA N/A
- LAES N/A
- EPS
- TSHA N/A
- LAES N/A
- Revenue
- TSHA $8,333,000.00
- LAES $20,135,000.00
- Revenue This Year
- TSHA N/A
- LAES N/A
- Revenue Next Year
- TSHA N/A
- LAES N/A
- P/E Ratio
- TSHA N/A
- LAES N/A
- Revenue Growth
- TSHA N/A
- LAES N/A
- 52 Week Low
- TSHA $1.19
- LAES $0.29
- 52 Week High
- TSHA $4.32
- LAES $11.00
- Technical
- Relative Strength Index (RSI)
- TSHA 54.31
- LAES 44.40
- Support Level
- TSHA $1.66
- LAES $2.40
- Resistance Level
- TSHA $1.77
- LAES $2.94
- Average True Range (ATR)
- TSHA 0.11
- LAES 0.38
- MACD
- TSHA 0.01
- LAES 0.02
- Stochastic Oscillator
- TSHA 47.62
- LAES 52.45
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.